Key Takeaways
- Richard Pazdur, former FDA drug regulator, expressed concern over the agency’s loss of expertise following significant layoffs and policy changes.
- Pazdur criticized the erosion of the “firewall” between political appointees and drug review processes, leading to potential corruption in decisions.
- He advocates for reinstituting advisory committees for enhanced transparency in decision-making and calls for modernizing drug development regulations.
Lamenting the Loss of Expertise
Richard Pazdur, M.D., former top drug regulator at the FDA, shared his concerns about the agency’s declining expertise at a recent event during the American Association for Cancer Research (AACR) meeting in San Diego. He pointed out that there has been a systematic attack on the federal workforce, culminating in chaotic layoffs on April 1, 2025, which are currently under scrutiny. Pazdur described entering the FDA building and finding that many employees’ access badges no longer worked, with no clear knowledge of who had been let go or the future structure of the agency.
Pazdur highlighted that the layoffs have led to heightened anxiety among remaining staff, fearing they might be next. Despite these challenges, he expressed confidence in the capabilities of the remaining personnel. He retired from the FDA in December after a brief stint as director of the Center for Drug Evaluation and Research and has a notable history with the agency.
Policy Changes and the Erosion of Regulatory Integrity
Pazdur criticized the FDA’s recent trend of announcing policy changes without consulting career staff, indicating that the essential separation between political appointees and drug review processes has diminished. This situation has raised concerns about potential corruption, particularly regarding the controversial Commissioner’s National Priority Voucher program. Pazdur noted that, in the past, he didn’t engage in discussions about drug approvals with the commissioner, indicating a shift in how regulatory decisions are made.
Additionally, he is worried about the FDA’s decreased use of advisory committees, which consist of external experts who can provide critical insights into complicated scientific issues. Pazdur underscored the importance of these committees, as they contribute transparency in the decision-making process that cannot be matched by formal communications like complete response letters.
Advocacy for Reforms
Having served on the FDA’s Oncologic Drugs Advisory Committee, Pazdur suggests that there is a need for reform in how these committees operate, including streamlining meetings and ensuring a more diverse membership reflective of industry and patient advocacy groups.
Despite his concerns about the agency’s trajectory, Pazdur has no desire to return to the FDA under the current administration, stating, “Not under this administration. For obvious reasons.”
China and Global Drug Development
Additionally, Pazdur addressed the growing biotech industry in China during an industry event. He emphasized viewing the situation through a global lens, advocating for international collaboration, as demonstrated by the FDA’s Project Orbis, which aims to enhance cooperation in drug reviews across multiple countries.
Pazdur believes the U.S. could learn from China’s efficient methods in conducting phase 1 trials, aligning with ongoing discussions about the need for faster early-stage studies. While asked about initiatives to create alternatives to the investigational new drug (IND) pathway, he noted there have been no current initiatives, indicating that existing regulations may need to be updated due to advancements in drug development.
Finally, Pazdur reflected on his evolving stance towards single-arm trials, acknowledging a more flexible approach developed over his career, especially regarding oncology drugs showing meaningful patient impact. However, he remained firm that he has not changed his views on other regulatory matters over the years.
The content above is a summary. For more details, see the source article.